why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
300×250 Ad Slot

Drug FDA Status

Showing 120 of 139 result(s) (Page 12 of 14)
Drug Name: Xdemvy

Active Ingredient: lotilaner

Approval Date: 2023-07-25

Description: To treat Demodex blepharitis

Drug Name: Vanflyta

Active Ingredient: quizartinib

Approval Date: 2023-07-20

Description: To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria

Drug Name: Beyfortus

Active Ingredient: nirsevimab-alip

Approval Date: 2023-07-17

Description: To prevent respiratory syncytial virus (RSV) lower respiratory tract disease
Press Release
Drug Trials Snapshot

Drug Name: Ngenla

Active Ingredient: somatrogon-ghla

Approval Date: 2023-06-27

Description: To treat growth failure due to inadequate secretion of endogenous growth hormone
Drug Trials Snapshot

Drug Name: Rystiggo

Active Ingredient: rozanolixizumab-noli

Approval Date: 2023-06-26

Description: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive

Drug Name: Litfulo

Active Ingredient: ritlecitinib

Approval Date: 2023-06-23

Description: To treat severely patchy hair loss
Drug Trials Snapshot

Drug Name: Columvi

Active Ingredient: glofitamab-gxbm

Approval Date: 2023-06-15

Description: To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy
Drug Trials Snapshot

Drug Name: Inpefa

Active Ingredient: sotagliflozin

Approval Date: 2023-05-26

Description:

?To treat heart failure 

Drug Name: Posluma

Active Ingredient: flotufolastat F 18

Approval Date: 2023-05-25

Description: To use with positron emission tomography imaging in certain patients with prostate cancer
Drug Trials Snapshot

Drug Name: Paxlovid

Active Ingredient: nirmatrelvir, ritonavir

Approval Date: 2023-05-25

Description: To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19
Press Release
Drug Trials Snapshot

300×250 Ad Slot